Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE vs CALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
Hypertension (chronic stable angina is not an approved indication in the US; however, it is used off-label for short-term treatment of hypertension in hospitalized patients and for subarachnoid hemorrhage to prevent vasospasm.,Off-label: short-term management of hypertension in hospitalized patients, prevention of cerebral vasospasm after subarachnoid hemorrhage.
Angina pectoris (chronic stable, vasospastic, unstable),Essential hypertension,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT)
20-40 mg orally three times daily.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Hepatic metabolism primarily via cytochrome P450 isoenzymes CYP3A4 and CYP2C8, with minor contributions from CYP2D6.
Extensively metabolized in the liver via CYP3A4, CYP1A2, and CYP2C8 isoenzymes; undergoes N-dealkylation and O-demethylation; first-pass metabolism results in low bioavailability (20-35%).
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
>95% bound to albumin and alpha-1 acid glycoprotein
Approximately 90% bound to plasma proteins, primarily albumin.
0.6-1.2 L/kg (large Vd due to extensive tissue binding)
Vd 4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
Oral: 35-60% (first-pass metabolism; increased with hepatic disease)
Oral bioavailability is 20-35% due to extensive first-pass hepatic metabolism; IV bioavailability is 100%.
For GFR < 30 m L/min: initiate at 20 mg orally twice daily.
Cr Cl <30 m L/min: reduce dose by 50% and monitor carefully.
Child-Pugh class B or C: reduce dose by 50% and titrate slowly.
Child-Pugh A: 50% of normal dose; Child-Pugh B: 25% of normal dose; Child-Pugh C: contraindicated or use with extreme caution.
Not established; safety and efficacy not determined.
Oral: 4-8 mg/kg/day in 3 divided doses; IV: 0.1-0.3 mg/kg over 2 minutes, max 5 mg.
Initiate at 20 mg orally twice daily; titrate cautiously.
Start at lowest dose (e.g., 40 mg 3 times daily) and titrate slowly; monitor for hypotension and bradycardia.
No FDA black box warning.
Contains verapamil hydrochloride. Risk of serious adverse effects including hypotension, bradycardia, AV block, and cardiac arrest. Must not be administered to patients with severe left ventricular dysfunction, cardiogenic shock, or sick sinus syndrome (unless paced).
Hypotension (especially in patients with ventricular dysfunction or those receiving beta-blockers), increased angina (rare, more common with dihydropyridines), peripheral edema, congestive heart failure (use caution in patients with severe left ventricular dysfunction), hepatic impairment (reduce dose), renal impairment (monitor blood pressure), abrupt discontinuation may cause angina exacerbation.
May cause hypotension, bradycardia, AV block, and exacerbation of heart failure. Avoid in patients with pre-existing conduction abnormalities. Use caution with beta-blockers, digoxin, and CYP3A4 inhibitors. Abrupt withdrawal may exacerbate angina. May increase lithium and carbamazepine levels.
Hypersensitivity to nicardipine or any dihydropyridine, advanced aortic stenosis (may reduce coronary perfusion), second- or third-degree AV block (unless paced), sick sinus syndrome (unless paced), cardiogenic shock, concomitant use with strong CYP3A4 inducers (e.g., rifampin) due to decreased efficacy.
Severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), atrial flutter/fibrillation with accessory bypass tract (e.g., WPW syndrome), concurrent use of IV beta-blockers.
Grapefruit and grapefruit juice increase nicardipine exposure and should be avoided. High-fat meals may reduce absorption; take consistently with or without food. Alcohol may enhance hypotensive effects.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing verapamil levels and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not extent; take consistently with regard to meals.
Cardene (nicardipine) is classified as FDA Pregnancy Category C. In animal studies, nicardipine was associated with embryotoxicity, fetotoxicity, and teratogenicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use in the first trimester should be avoided if possible; in the second and third trimesters, potential benefits must outweigh risks, particularly due to possible maternal hypotension and fetal hypoxia.
First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion; avoid use for pregnancy-induced hypertension due to risk of fetal hypoxia.
Nicardipine is excreted in human breast milk. The M/P ratio is approximately 0.7. Limited data suggest that concentrations in breast milk are low relative to therapeutic doses, but the effects on the nursing infant are unknown. Caution is advised.
Verapamil (CALAN) is excreted into breast milk; M/P ratio approximately 0.6. The relative infant dose is low (estimated <5% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution in preterm infants or those with renal impairment.
Pregnancy may alter the pharmacokinetics of nicardipine due to increased plasma volume and altered hepatic metabolism. However, specific dose adjustment recommendations are not established. In hypertensive emergencies, intravenous nicardipine is often used at standard doses with careful titration to avoid maternal hypotension. Oral doses may require titration based on response, starting at 20 mg three times daily.
Pregnancy may increase clearance of verapamil; monitoring of therapeutic effect advised. Dose may need adjustment based on clinical response. Avoid use in pregnancy-induced hypertension.
CARDENE (nicardipine) is a dihydropyridine calcium channel blocker used intravenously for acute hypertension. Onset is rapid (1-2 minutes), making it ideal for hypertensive emergencies. It is metabolized hepatically; reduce dose in hepatic impairment. Does not cause reflex tachycardia as prominently as other dihydropyridines. Contraindicated in advanced aortic stenosis. Can be used for hypertension during pregnancy but with caution.
Calan (verapamil) is a class IV antiarrhythmic and calcium channel blocker. Use caution in patients with hepatic impairment due to reduced clearance; dose adjustment may be needed. Avoid in patients with pre-existing bradycardia, second- or third-degree AV block, or sick sinus syndrome unless a pacemaker is present. May increase digoxin levels; monitor digoxin concentrations. Use with caution in patients with hypertrophic cardiomyopathy. For IV administration, have calcium gluconate available to reverse hypotension or bradycardia. Not recommended for use in acute myocardial infarction or cardiogenic shock.
Take exactly as prescribed; do not stop abruptly.,May cause dizziness or lightheadedness; avoid driving until you know how it affects you.,Avoid grapefruit and grapefruit juice as they may increase drug levels.,Report irregular heartbeat, shortness of breath, or swelling of the ankles or feet.,Keep all appointments for blood pressure monitoring.
Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.,Avoid grapefruit juice as it can increase verapamil levels and risk of side effects.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid alcohol as it may worsen side effects like dizziness or low blood pressure.,Report symptoms of bradycardia (slow heart rate), palpitations, shortness of breath, or swelling of ankles/feet.,This medication may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume grapefruit or its juice during treatment.,Keep a regular medication schedule and do not change brands without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE vs CALAN, answered by our medical review team.
CARDENE is a Calcium Channel Blocker that works by Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.. CALAN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE and CALAN depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE is: 20-40 mg orally three times daily.. The standard adult dose of CALAN is: Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE and CALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE is classified as Category C. Cardene (nicardipine) is classified as FDA Pregnancy Category C. In animal studies, nicardipine was associated with embryotoxicity, fetotoxicity, and teratogenicity at high doses. . CALAN is classified as Category C. First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.